A lawsuit and settlement has been reached for the class action suit against Eliquis, a blood thinner. The drug manufacturer will pay out $345 million to patients who took the medication between October 1, 2015 and September 30, 2016. How should this case be viewed?
The “eliquis recall 2020” is a lawsuit and settlement that was filed in the year of 2020. The case involved the drug Eliquis, which was manufactured by Bristol-Myers Squibb. The case has been settled out of court for $1 billion dollars.
Eliquis is an anticoagulant that is used to prevent deep vein thrombosis (DVT), pulmonary embolism (PE), strokes, and blood clots. Despite promises of greater safety and efficacy when compared to the older anticoagulant warfarin, there is no evidence that Eliquis is safer or more effective.
For claimed Eliquis-related injuries and fatalities, patients have filed lawsuits against drugmakers Bristol-Myers Squibb and Pfizer.
Eliquis, unlike warfarin, does not have an antidote or need frequent blood monitoring to help avoid serious bleeding episodes. The Eliquis approval procedure has also been questioned when anomalies were discovered at a clinical study site.
For suspected Eliquis-related injuries and fatalities, lawsuits have been brought against drugmakers Bristol-Myers Squibb and Pfizer.
Eliquis Side Effects That Are Serious
Eliquis may induce significant, permanent, and even deadly internal bleeding. The following are some of the possible side effects of Eliquis:
- bleeding in the intestines
- Kidney thrombosis
- Rectal bleeding is a common problem.
- Bleeding from the eyes
- Bleeding in the spine
- Hemorrhage in the brain
All blood thinners may induce bleeding since they inhibit blood coagulation. However, Eliquis is potentially more harmful than warfarin, the industry-standard blood thinner for decades.
The new class of blood thinners is touted as an alternative to warfarin that has a number of advantages over the older medication, including the elimination of regular blood tests and the elimination of severe dietary restrictions. While patients may find frequent anticoagulant blood tests to be inconvenient, evidence shows that assessing coagulation function might aid in the assessment of bleeding risk.
While Eliquis is touted as causing less significant bleeding than warfarin, this advantage comes with a caveat: large bleeding may be cured with Vitamin K in the case of warfarin. Eliquis has no antidote to halt the bleeding. To put it another way, once an Eliquis patient has severe bleeding, a doctor may not be able to stop it.
Irregularities in the Eliquis Clinical Trial
Aristotle is an excellent illustration of the close relationships that exist between the pharmaceutical business and researchers.
Clinical studies used to support Eliquis approval were allegedly rigged, resulting in patients taking a dangerous medicine that should never have been on the market in the first place, according to the lawsuits.
The FDA postponed Eliquis approval for nine months due to misbehavior, mistakes, and an alleged cover-up at a Chinese clinical study site. According to the FDA, the errors revealed a “pattern of insufficient trial conduct and monitoring.”
ARISTOTLE is the name of the trial in issue (Apixaban for Reduction in Stroke and Other Thrombotic Events in Atrial Fibrillation). The clinical experiment had a number of problems, according to FDA documents:
- Failure to disclose unfavorable medical outcomes (including deaths)
- Reports of adverse occurrences were received late.
- Medical outcomes are not included in the analysis.
- A large number of patients were given the incorrect medicine or dosage of the wrong drug.
The Aristotle research was finally published in the New England Journal of Medicine, but it was widely panned, notably by former NEJM editor-in-chief Arnold Relman, who pointed out problems in the study and claimed that commercial interests affected its release.
The trial failed to establish that Eliquis was more effective than warfarin, according to Relman, and safety statistics may have been slanted in favor of Eliquis. He used Aristotle as an example of how close relationships between the pharmaceutical business and academics may lead to skewed findings. Bristol Myers Squibb workers made up at least three of the study’s authors.
Follow the money to see why Bristol-Myers/Pfizer were so keen to release a new treatment that is barely (if at all) better than warfarin. Eliquis is more than ten times more expensive than warfarin on a yearly basis.
Allegations in the Eliquis Lawsuit
Over 130 lawsuits have been brought against Bristol-Myers Squibb and Pfizer for claimed Eliquis-related injuries and fatalities. Plaintiffs in Eliquis cases accuse the drugmakers of a variety of things, including the following:
- Eliquis’ absence of a bleeding reversal agent was not adequately warned about.
- Eliquis’ safety has been exaggerated while its hazards have been minimized.
- Eliquis was not properly tested since it was not thoroughly tested.
- Putting a medicine on the market with unreasonably harmful adverse effects
- Breaching a drugmaker’s obligation to offer fairly safe medicines to market
- Negligently promoting and advocating Eliquis without adequate awareness of the risks
- Keeping product safety information hidden from the general population
- Profits come before patient safety.
- Fraudulent behavior during Eliquis testing
- As a consequence of these actions and omissions, patients have been injured and have died.
Lawsuits that are similar
Both Eliquis and Pradaxa, two new generation blood thinners, have been sued for bleeding adverse effects. In 2014, almost 4,000 Pradaxa claims were resolved for $650 million.
These medications are similar to warfarin in that they are touted as being safer, more effective, and simpler to use. Manufacturers are accused of hiding prescription side effects and creating patient injury via their carelessness, according to the lawsuits filed over these medications.
Eliquis lawsuits are only now being brought in substantial numbers since it was the last of these treatments to be authorized and has been on the market for the shortest duration. More complaints are anticipated to be filed as more people become aware of the relationship between the medicine and life-threatening bleeding.
If a significant number of cases are filed against Eliquis, the case may be designated as a multidistrict litigation (MDL).
What Can a Lawsuit Do for You?
If your medicine caused difficulties or severe adverse effects, you may be able to collect damages for medical expenditures, as well as lost income or diminished earning potential, via a lawsuit. Physical pain, emotional agony, and a lower quality of life may all be covered by a lawsuit settlement.
For a free legal consultation, please contact us. We’ll go through your rights, answer any questions you have, and let you know whether you have a case against the manufacturer.
It costs nothing to have your claim examined, and you will not be charged anything unless and until our lawyers win your case. We’ve gotten $4 billion for our clients thus far.
Have you found what you’re looking for?
Watch This Video-
The “the truth about eliquis” is a lawsuit and settlement that was released in 2017. The lawsuit alleges that Pfizer, the company who makes Eliquis, knew of the risks associated with their drug but did not warn patients.
Frequently Asked Questions
Is there a class action lawsuit against Eliquis?
A: Eliquis is a drug used to prevent blood clots in the veins.
Is Eliquis being recalled?
A: No, Eliquis is not being recalled.
How many people have died because of Eliquis?
A: It is difficult to answer this question. The best way for you to find out would be by looking at the side effects of Eliquis and how serious they are, as well as speaking with your doctor about them if you need more information.
- eliquis lawsuit 2021
- eliquis complaints
- eliquis blood thinner compensation
- eliquis lawsuit 2020
- eliquis lawsuit settlement amounts